Bristol-Myers Squibb Company Valuation – June 2018 $BMY
Bristol-Myers Squibb Co is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.
Bristol-Myers Squibb Co Valuation – September 2017 $BMY
Bristol-Myers Squibb Co is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.
Bristol-Myers Squibb Company Valuation – February 2016 $BMY
Bristol-Myers Squibb Co does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.
27 Companies in the Spotlight This Week – 12/20/14
We evaluated 27 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham’s value investing formulas in order to determine an intrinsic value for each. Here’s a summary of the ModernGraham Valuations.
Bristol-Myers Squibb Company Annual Valuation – 2014 $BMY
Bristol-Myers Squibb is not suitable for either the Defensive Investor or the Enterprising Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.
10 Companies in the Spotlight This Week – 12/21/13
We looked at 10 different companies this week.  Here’s a summary of the ModernGraham Valuations.  For more detailed analysis, click on the name of the company.  To see screens of all of our valuations, be sure to get a copy of this month’s edition of ModernGraham Stocks and Screens! The Elite (Defensive or Enterprising and Undervalued) […]
ModernGraham Valuation: Bristol-Myers Squibb Co. (BMY)
Bristol-Myers Squibb Co. has displayed stable earnings and dividends, but does not currently qualify for either the Defensive Investor or the Enterprising Investor. For the Defensive Investor, the company does not have a high enough current ratio and trades at high PEmg and PB ratios.